# Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT Carcinoma

> **NCT07050186** · PHASE2 · RECRUITING · sponsor: **Northwestern University** · enrollment: 15 (estimated)

## Conditions studied

- Metastatic NUT Carcinoma
- Unresectable NUT Carcinoma

## Interventions

- **PROCEDURE:** Biopsy Procedure
- **PROCEDURE:** Biospecimen Collection
- **BIOLOGICAL:** Cemiplimab
- **PROCEDURE:** Computed Tomography
- **OTHER:** Digital Photography
- **PROCEDURE:** Magnetic Resonance Imaging
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT07050186
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-15
- **Primary completion:** 2030-11-20
- **Final completion:** 2035-11-20
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07050186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07050186, "Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07050186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*